Home

Preclinical

Parkinson's Disease

Read time: 3 min

Congress highlights

Getting rid of alpha-synuclein – active and passive immunotherapy, or maybe targeting LRRK2?

Immunotherapy is an established treatment option for many forms of cancer, and recently received...

Read time: 3 min

USP30 a valid therapeutic target

The idea that mitochondrial dysfunction is implicated in Parkinson’s Disease is not new, but...

Read time: 4 min

Schizophrenia – from prodrome to psychosis

Psychosis is preceded by a 3–4 year prodromal phase in 75% of patients, but only 25% of...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Unraveling network dysfunction in Alzheimer’s Disease

Amyloid precursor protein/amyloid-beta and tau appear to act together to cause deficits in synaptic...

Alzheimer's Disease

Read time: 4 min

Biomarkers to enable early diagnosis and intervention and to monitor progression

Clinical diagnosis of Alzheimer’s disease (AD) is difficult and has an error rate of 40%....

Read time: 3 min

From genes to schizophrenia and more

Some trajectories of cognitive development is altered in individuals with schizophrenia. At a...

Read time: 4 min

Congress highlights

Mutual benefits: Public–Private Partnerships in CNS Research

Public–Private Partnerships are being developed worldwide to facilitate collaboration between...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Could astrocyte activation initiate AD pathology 20 years before diagnosis?

Neuroimaging techniques demonstrate a 20-year pathophysiological pathway preceding the development...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Essential elements for Alzheimer’s disease clinical trials

Stronger links between novel agents and their targets, more precise selection of patients, and...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Dietary interventions that may lower the risk of Alzheimer’s disease

Increasing evidence shows that dietary interventions may lower the risk of developing Alzheimer...

Read time: 4 min

GABA dysfunction – preclinical and clinical imaging perspectives in schizophrenia

The association between abnormal interneuronal function and neuropsychiatric conditions is...

Alzheimer's Disease

Read time: 4 min

β-amyloid remains a compelling target

Neuropathology, genetics and biology all support the idea that β-amyloid is central to the...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country